Answers are grounded in this paper and cite their sources.
In December 2025, an H6N2 avian influenza virus (A/chicken/Henan/NL04/2025, NL04) was isolated from a chicken outbreak in Henan, China with 15% field mortality and severe respiratory disease. Genome sequencing confirmed it is a novel reassortant possessing a waterfowl‑origin H6‑derived HA, H9N2‑derived NA, and the complete internal‑gene cassette of the H9N2 G57 genotype. Although NL04 caused only mild clinical disease and 100% survival in experimentally infected specific-pathogen-free (SPF) chickens, prominent respiratory‑tract histopathological damage was observed, revealing a marked phenotypic discrepancy between laboratory outcomes and severe field‑reported mortality that is likely driven by complex commercial‑farm risk factors. Tissue viral loads in SPF chickens peaked in nasal turbinates and the Harderian gland, confirming its predominant respiratory tropism. In BALB/c mice, NL04 exhibited limited nasal replication, indicating low mammalian‑adaptation potential. We further evaluated an inactivated vaccine candidate based on NL04. The vaccine induced robust humoral immunity, reduced viral shedding after homologous challenge, and elicited cross‑neutralizing antibodies against a heterologous H6N1 isolate. Our findings highlight the veterinary relevance of this unique H6N2 reassortant and stress the value of continuous genomic surveillance among poultry to prevent emerging avian‑influenza threats.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: